Moleculin Biotech rises as cancer drug shows no heart damage in trials

Moleculin Biotech

13/01/2026 14:09

** Shares of drug developer Moleculin Biotech MBRX.O rise 2.2% to $4.14 premarket

** Co says its experimental cancer drug, annamycin, showed no signs of causing heart damage in patients in five clinical trials

** Independent expert reviewed data from 90 patients with leukemia and sarcoma; found no heart issues - MBRX

** Annamycin, also called naxtarubicin, tested for leukemia and sarcoma spread

** Leukemia is a blood cancer; sarcoma is a cancer that starts in soft tissues and can spread to lungs

** Drug being studied alone and with chemotherapy; late-stage leukemia trial ongoing - MBRX

** Co says it is working to secure funding and will monitor patients long-term for heart issues

** As of last close, stock down ~92% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))